CD163 and neoplasm: Moreover, NLGP reduces the tumor-promoting phenotype M2, amongst tumor-associated macrophages (TAMs) as it downregulates the secretory (Ym1, FIZZ1 etc.)[15] and cell-surface (CD206, CD163 etc.)[16] M2 markers with a simultaneous increase of antitumor M1 markers (CD16, CD32 etc.)[17] in such cells.